MedTrace Logo

The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section

NCT02847013 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2020-01-31

No results posted yet for this study

Summary

This present investigation aims to determine whether a transversus abdominous plane(TAP) block, utilizing liposomal bupivacaine (Exparel), at the conclusion of a cesarean section decreases post-operative pain. The hypothesis is that performance of the TAP block with liposomal bupivacaine will decrease post-operative narcotic use.

Conditions

Interventions

DRUG

TAP block w Liposomal bupivacaine

TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)

PROCEDURE

TAP block w normal saline

TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Jaimey Pauli, MD · Milton S. Hershey Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Primary Completion
2019-12-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02847013 on ClinicalTrials.gov